KB-0742

• Description :

  KB-0742 is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 has potent anti-tumor activity[1][2].

• CAS Number :

  [2416873-83-9]

• UNSPSC :

  12352005

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/kb-0742.html

• Concentration :

  10mM

• Purity :

  99.38

• Solubility :

  DMSO : 175 mg/mL (ultrasonic)

• Smiles :

  N[C@@H]1C[C@@H](NC2=CC(C(CC)CC)=NC3=CC=NN23)CC1

• Molecular Formula :

  C16H25N5

• Molecular Weight :

  287.40

• References & Citations :

  [1]André Richters, et al. Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell Chem Biol. 2020 Oct 20; S2451-9456 (20) 30380-9.|[2]Freeman DB, et al. Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers. J Med Chem. 2023 Dec 14;66 (23) :15629-15647.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  CDK1; CDK2; CDK3; CDK4; CDK5; CDK6; CDK7; CDK8; CDK9

• Citation 01 :

  University of California, Irvine. 2024.|bioRxiv. 2025 Nov 3:2025.11.02.685764.|Cell Chem Biol. 2025 Apr 17;32 (4) :542-555.e10.